Post-earnings recap
Reported
Thu, Aug 6, 2026
EPS actual
$2.37
EPS est.
$1.49
EPS surprise
+59.06%
1-day move
-0.02%
ICU Medical reported a strong EPS figure that significantly exceeded expectations, indicating solid profitability. However, the stock experienced a slight decline of 0.02%, suggesting that investors may have been looking for more comprehensive guidance or additional insights from management. The lack of revenue data and management commentary may have contributed to the muted stock reaction.
| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $2.37 | N/A | +59.06% |
| Revenue | N/A | N/A | N/A |
No transcript is on record, and the analysis is based solely on numerical results.
ICU Medical, Inc. is a healthcare company that specializes in medical supplies, particularly infusion systems and devices. With a market cap of $5 billion, the company plays a crucial role in providing essential products that improve patient care and safety in hospitals and healthcare facilities.
Last quarter
In Q1-2026, ICU Medical reported an EPS of $1.97, significantly exceeding expectations by 48%. The stock reacted positively, gaining 2.91% the following day.
Management promises and guidance
EPS beat streak
8Q
EPS beat rate
100%
Avg EPS surprise
+74.78%
Avg 1-day reaction
+1.12%
Overall, expectations are high for ICU Medical as it has consistently beaten EPS estimates in recent quarters. Investors are looking for continued strong performance and any signs of revenue growth.
Bull case
If ICU Medical maintains its trend of beating EPS estimates and shows strong revenue growth, it could signal robust demand for its products, leading to a positive stock reaction.
Bear case
Conversely, if the company fails to meet expectations or shows signs of slowing growth, it could lead to a negative market reaction, especially given the high expectations.
The print will turn on these.
Q1
What will the EPS be for Q2-2026?
Given the company's strong track record of beating EPS estimates, this number will be crucial in determining investor sentiment.
Q2
How is revenue growth trending in key markets?
Understanding revenue growth will provide insight into the company's market position and future prospects.
—
Est. EPS
$1.48
Est. Rev
$3.3B
Impl. Move
±16.9%
Why consensus could be wrong
The Street may underestimate ICU Medical's ability to maintain its growth trajectory, especially given its recent innovations and market expansions.
Supporting evidence
The company has consistently beaten EPS estimates, indicating stronger-than-expected demand.
Options pricing suggests a higher volatility than historical averages, hinting at potential surprises.
Key risk
If the EPS comes in below $1.50, it could challenge the bullish sentiment surrounding the stock.
Pre-commit to what would confirm each case.
The core debate this quarter revolves around whether ICU Medical can sustain its impressive earnings momentum amid rising market expectations.
Bull confirmed if
An EPS of $2.10 or better would confirm the bull case, indicating continued strong performance.
Bear confirmed if
An EPS below $1.50 would confirm the bear case, suggesting a potential slowdown in growth.
What the market is pricing for the move.
Implied Move
±5.31%
Historical Avg
±2.2%
The options market is pricing in a significant move of over 5%, indicating that traders expect some volatility around the earnings report.
Options are pricing ±5.3% while ICUI has averaged ±2.2% over the last 8 prints — setup is pricing rich.
ATM IV
0.5%
30d HV
35.6%
Smart-money positioning from the most recent 13F filings.
Institutional
115.79%
of float
Insider
1.75%
of float
Holders
397
institutions
Top Holders· as of Jun 2026
Blackrock Inc.
3,753,409 sh · $585.6M
15.02%
4.0%
Likely market behavior by outcome. Not investment advice.
Beat & raise
If ICU Medical beats expectations, history suggests a positive stock reaction of around +0.93%, confirming strong demand for its products.
In line / cautious
If results are in line with expectations, the stock may see muted movement as investors await further guidance from management.
Miss
A miss could lead to a significant decline, with historical patterns suggesting an average drop of around -2.31%.
The lines on the call that would change the story.
Jupiter Topco LLC
2,781,620 sh · $434.0M
11.13%
100.0%
Vanguard Portfolio Management LLC
1,470,583 sh · $229.5M
5.88%
2.3%
Fuller & Thaler Asset Management Inc.
1,298,127 sh · $202.5M
5.19%
6.4%
Vanguard Capital Management LLC
1,123,237 sh · $175.3M
4.49%
1.0%
13F filings updated quarterly. Position deltas show change in shares vs. the prior quarter.